BLU 667 companion diagnostic - Blueprint Medicines/Thermo Fisher Scientific

Drug Profile

BLU 667 companion diagnostic - Blueprint Medicines/Thermo Fisher Scientific

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Blueprint Medicines; Thermo Fisher Scientific
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 31 Oct 2017 Blueprint Medicines and Thermo Fisher Scientific agree to co-develop BLU 667 companion diagnostic in USA for Non-small cell lung cancer
  • 15 Mar 2017 Phase-I clinical trials in Non-small cell lung cancer (Diagnosis) in USA (unspecified route) (NCT03037385)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top